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ABSTRACT
Aim To evaluate a standardised MRI acquisition protocol
and a new image rating scale for disease severity in
patients with progressive supranuclear palsy (PSP) and
multiple systems atrophy (MSA) in a large multicentre
study.
Methods The MRI protocol consisted of two-
dimensional sagittal and axial T1, axial PD, and axial and
coronal T2 weighted acquisitions. The 32 item ordinal
scale evaluated abnormalities within the basal ganglia
and posterior fossa, blind to diagnosis. Among 760
patients in the study population (PSP¼362, MSA¼398),
627 had per protocol images (PSP¼297, MSA¼330).
Intra-rater (n¼60) and inter-rater (n¼555) reliability
were assessed through Cohen’s statistic, and scale
structure through principal component analysis (PCA)
(n¼441). Internal consistency and reliability were
checked. Discriminant and predictive validity of extracted
factors and total scores were tested for disease severity
as per clinical diagnosis.
Results Intra-rater and inter-rater reliability were
acceptable for 25 (78%) of the items scored ($0.41).
PCA revealed four meaningful clusters of covarying
parameters (factor (F) F1: brainstem and cerebellum; F2:
midbrain; F3: putamen; F4: other basal ganglia) with good
to excellent internal consistency (Cronbach a 0.75e0.93)
and moderate to excellent reliability (intraclass
coefficient: F1: 0.92; F2: 0.79; F3: 0.71; F4: 0.49). The
total score significantly discriminated for disease severity
or diagnosis; factorial scores differentially discriminated
for disease severity according to diagnosis (PSP: F1eF2;
MSA: F2eF3). The total score was significantly related to
survival in PSP (p<0.0007) or MSA (p<0.0005),
indicating good predictive validity.
Conclusions The scale is suitable for use in the context
of multicentre studies and can reliably and consistently
measure MRI abnormalities in PSP and MSA.
Clinical Trial Registration Number The study protocol
was filed in the open clinical trial registry (http://www.
clinicaltrials.gov) with ID No NCT00211224.
Progressive supranuclear palsy (PSP) and multiple
system atrophy (MSA) represent the two most
common causes of progressive neurodegenerative
akinetic rigid, multisystem syndromes (‘Parkinson’s
plus syndromes’; PPS) after idiopathic Parkinson’s
disease (IPD).1 2 In the early stages, it can be difﬁcult
to differentiate PSP and MSA from IPD. Symptoms
of PSP include oculomotor abnormalities, early falls,
pyramidal symptoms and frontal lobe dysfunction.3
Patients with MSA exhibit autonomic failure, cere-
bellar and pyramidal involvement.4 5 For the
majority of patients with PSP and MSA, the course
of the disease is one of relentless progression,
increasing disability and death, with a median
survival of 5e10 years from onset of symptoms.4 6 7
The disease processes in MSA and PSP involve
many brain areas but particularly the basal ganglia,
brainstem and cerebellum.8e10 Although a number
of MRI abnormalities corresponding to underlying
pathological changes have been described in PSP
and MSA,11e16 these have not been subject to
a systematic assessment. Furthermore, existing
studies have used small samples, limiting the
conclusions that can be drawn for routine
practice.17e19 Several studies have examined the
usefulness of quantitative measurements of
atrophy taken in speciﬁc regions of interest.11 17e21
However, these restricted measurements do not
capture the full extent of abnormalities seen on
MRI. In order to provide a validated framework for
a systematic and semiquantitative approach to
assessment of MRI abnormalities in large multi-
centre studies of PPS, and to provide an outcome
measure of disease progression in clinical trials, we
incorporated a prospective standardised collection
of MRIs as an ancillary component of the Neuro-
protection and Natural History in Parkinson’s Plus
Syndromes (NNIPPS) study.22 NNIPPS was
designed to investigate the natural history of
Parkinson’s plus syndromesdPSP and MSAdas
part of a double blind, placebo controlled, rando-
mised, multicentre (n¼44) trial in France, Germany
and the UK.
In this paper, we present the standardised MRI
acquisition protocol and validation of the NNIPPS
MRI rating scale which was intended to measure
disease severity and progression in the context of
large multicentre randomised clinical trials.
METHODS
Subjects
From April 2000 to July 2002, subjects were
included in the trial according to NNIPPS diag-
nostic criteria, and followed-up for 3 years or until
death, whichever came ﬁrst.22 Demographic infor-
mation and clinical scales were collected at entry
and during the course of the study (table 1).
Detailed information on trial design and results,
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including accuracy of diagnostic criteria, and clinical assess-
ments, has been reported previously.22 Members of the NNIPPS
Study Group are listed in Appendix 1.
Standardised MR image acquisition protocol
The main constraint in designing the acquisition protocol was to
determine sequences that would accommodate the variability in
scanner conﬁguration according to centres, and that could be
completed in 30 min, estimated as the maximum time these
patients would tolerate the scanner. The Imaging Technical
Committee determined, after initial testing and literature
review, that the acquisitions would: (i) be done on >1 T
magnets; (ii) include two-dimensional sagittal (at 5 mm slice
thickness) and three-dimensional T1 acquisitions allowing
reconstructions of axial images (at 5 mm slice thickness); and
(iii) include axial PD as well as axial and coronal T2 (at 3 mm
slice thickness). Axial slices were required to follow the bicallosal
plane, while coronal acquisitions had to be orthogonal to that
plane. The MRI protocol developed on a GE scanner (GE
Medical, Milwaukee, USA) and adapted by site investigators for
their particular conﬁguration is described in table 2.
At the time data acquisition began (2000), standardised
DICOM format was not available in every centre and hence the
use of printed ﬁlms was the only practical option for centralised
reading. The 160 images were printed by groups of 20 on 14317
inch ﬁlms, for a total of eight ﬁlms per patient, with care taken
to optimise contrast.
Image assessment
An image rating scale was developed in order to systematically
and semiquantitatively evaluate MRI signs within the basal
ganglia and posterior fossa (mesencephalon, pons and cere-
bellum), focussing on regionswhere both neuronal loss and gliosis
have been well documented either in PSP8 10 or in MSA.23 24
Selection of items to be scored was based on a literature review of
MRI abnormalities.11e16 In addition, based on neuropathology
ﬁndings and background clinical and radiological experience, new
undocumented items were added, including hyperintensity
within the ventral area of the globus pallidus (table 3, items 12
and 29), and the area between the red nucleus and substantia
nigra (table 3, item 15), as well as punctate upper mesencephalic
hyperintensities (table 3, items 18 and 31).
The semiquantitative scale was deﬁned by expert consensus
and included 32 parameters (table 3) with scores ranging from
0 (normal) to 3 (most severe) and one item for lateralisation
with categorical rating (item 9: 1¼R>L, 2¼L>R). For all items,
a score of 4 was given when the image was not interpretable and
a score of 9 when the image was missing. For structures well
seen in orthogonal planes (ie, pons, IVth ventricle, cerebellar
peduncles, mesencephalon, aqueduct of Sylvius, putamen and
internal globus pallidus), redundant reporting was achieved.
The scale was tested and standard operating procedures
(SOPs) deﬁned on an initial series of images from the ﬁrst 72
patients included in France. The scale was thereafter presented
to all raters in a training session, together with SOPs, and an
MRI atlas was built for scoring guidance (see supplementary
material available online only: NNIPPS-MRI atlas for scoring).
In each country, centralised double reading of each MRI scan
was performed blind to clinical diagnosis, by independent
experts. In case of disagreement between the two ratings on any
item (ie, scoring difference greater than 1), images were
re-evaluated by both raters until consensus was reached.
Statistical analysis
For each image series, ratings of the 32 items by individual
raters were recorded. All statistical analyses were performed
using SAS software V.11. Inter-rater reliability was assessed
using a simple k coefﬁcient for the binary parameter and a linear
weighted version of Cohen’s k statistics for ordinal data.25 26
Intra-rater reliability and training effect was assessed using
a weighted version of Cohen’s k statistics to compare scale
measures on the ﬁrst 30 patients and the last 30 patients
included in France, rated twice at 1 year intervals. Scale redun-
dancy was checked using between item correlation with
Spearman rank coefﬁcient.
Extraction of principal components (PCA) with varimax
rotation was performed on the scale using the consensus ratings
and excluding the categorical item 9, or the highly correlated
ones, to prevent overloading of signs, and using data from 441
patients with complete ratings for all parameters. Dimensional
factorial scores were calculated by summing items correlated to
the factor. Internal consistency of extracted components was
explored with Cronbach’s a coefﬁcient and inter-rater reliability
of factor scores with intraclass coefﬁcient (ICC).27 Dimensional
scores were calculated by summing items correlated to the
factor. Discriminant validity was checked comparing factor
scores and overall scores between (i) extreme groups of the
Clinician Global Impression of disease severity (CGI-ds, score
Table 1 Comparisons between MSA and PSP patients with MRI (Student’s t test or Pearson c2)
PSP (n[297) MSA (n[330) All (n[627) p Value
Gender (%F) 42 45 44 0.49
Mean (SD) age (years) (40e81) 67 (7) 62 (8) 64 (8) <0.001
Mean (SD) age at onset (years) (35e79) 64 (7) 57 (8) 60 (8) <0.001
Mean (SD) disease duration (years) (1e8) 3.9 (1.9) 4.3 (1.9) 4.1 (1.9) 0.002
Clinical Global Impression of severity (1e6)
Mean (SD) 3.6 (1.0) 3.6 (0.9) 3.6 (1.0) 0.73
Borderline/moderately ill (0e2) (%) 14 10 12
Markedly ill (3e4) (%) 67 73 70
Severely/extremely ill (5e6) (%) 19 17 18
Modified Hoehn and Yahr (0e5) (%)
No sign to mild bilateral disease (0e2) 15 24 20
Mild to moderate bilateral disease (3) 36 29 32 0.02
Severe disability (4) 30 32 31
Wheelchair bound (5) 19 15 17
Mean (SD) Schwab and England activities
of daily living scale (0e100%)
50 (23) 55 (24) 53 (24) 0.02
MSA, multiple systems atrophy; PSP, progressive supranuclear palsy.
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1e2 (borderlineemild) vs score 5e6 (severeeextremely severe))
with two-way ANOVA, including interaction, and (ii) diag-
nostic strata by Student’s t test. For each strata, sensitivity to
change in disease severity from borderlineemild to severee
extremely severe was summarised through Cohen’s d effect size
coefﬁcient (ES) for each factor and total score.28
Inter-rater and intra-rater reliability coefﬁcients were
interpreted according to proposed standards for strength of
agreement as: #0¼poor, 0.01e0.20¼slight, 0.21e0.40¼fair,
0.41e0.60¼moderate, 0.61e0.80¼substantial and 0.81e1.0¼almost
perfect.29 30 Individual item strength of agreement was considered as
acceptable for >0.40 (moderate to almost perfect); for
factorial score combining items, ICC threshold for acceptability
was raised to 0.70. Internal consistency of the factorial
scores were considered as acceptable for Cronbach >0.70. ES
coefﬁcients were interpreted as published: <0.5¼small,
0.5e0.79¼medium and $0.8¼large.28
For predictive validity, relation between factorial or total MRI
scale scores at inclusion and survival over the 3 year follow-up
was evaluated using univariate and multivariate Cox model
analysis.31
RESULTS
Demographics and clinical tests
A total of 760 patients were included in the intent to treat
analysis.22 MRI could not be performed in 133 patients. Within
the study centres, images were obtained using MRI scanners
Table 2 NNIPPS imaging protocol for Parkinson’s plus syndromes
Plane Acquisition Slice (mm) Number slices Film* TR (ms) TE (ms) FOV (mm) Matrix
Sagittal FGE T1 weighted 5 16 1 250e512 14e16 230e240 5123(224e256)
Axial bicallosal plane FSE proton density 3 40 2 5270e6000 12e20 230e240 2563(224e256)
Axial bicallosal plane FSE T2 weighted 3 40 2 5270e6000 75e110 230e240 2563(224e256)
Coronal orthogonal to the bicallosal plane FSE T2 weighted 3 40 2 4520e5200 96e110 230e240 5123(204e256)
Axialy 3D IR T1 weighted 0.9 160 2z 2500 IT¼500 Minimum 230e230 2563256
*Printed films contain 20 images each.
yThe whole cerebrum, including the cerebellum and brainstem, should be included.
zReconstruction of 20 slices at 5 mm thickness in the bicallosal plane, centred on the basal ganglia.
3D, three-dimensional; FGE, fast gradient echo; FOV, field of view; FSE, fast spin echo; IR, inversion recovery; NNIPPS, Neuroprotection and Natural History in Parkinson’s Plus Syndromes;
TE, echo time; TR, repetition time.
Table 3 NNIPPS MRI scale: inter-rater and intra-rater reliability
Image Measurement Inter-rater (n[555) Intra-rater (n[60)
Sagittal T1 1. Pontine atrophy 0.59 0.80
2. Cerebellar atrophy 0.56 0.78
3. Fourth ventricle enlargement 0.59 0.66
4. Midbrain atrophy 0.60 0.62
5. Aqueduct of Sylvius enlargement 0.53 0.63
Axial PD 6. Ponto-cerebellar atrophy (Cross sign) 0.70 0.88
7. Cerebellar peduncles hyperintensities 0.64 0.94
Axial T2 8. Putamen marginal lateral rim 0.52 0.67
9. Lateralisation of item 8 0.27* 0.72*
10. Putamen marginal postero-medial rim 0.29 0.68
11. Hypointense posterior putamen 0.42 0.41
12. Hyperintense internal pallidum ventral area 0.63 0.79
13. Hypointense red nuclei 0.37 0.61
14. Hypointense substantia nigra 0.30 0.55
15. Hyperintensity between red nucleus and
substantia nigra
0.26 0.52
16. Aqueduct of Sylvius enlargement 0.51 0.60
17. Periaqueductal hyperintensity 0.45 0.41
18. Punctate mesencephalic hyperintensities 0.47 0.66
19. Increased interpeduncular angle 0.49 0.62
20. Ponto-cerebellar atrophy (Cross sign) 0.80 0.72
21. Cerebellar peduncles hyperintensities 0.65 0.81
22. Middle cerebellar peduncles atrophy 0.60 0.72
23. Hypointense dentate nuclei 0.63 0.72
24. Fourth ventricle enlargement 0.64 0.71
25. Hyperintense base of the pons 0.35 0.76
26. Peripheral patches 0.60 0.69
Coronal T2 27. Putamen marginal lateral rim 0.45 0.75
28. Putamen marginal inferior rim 0.17 0.38
29. Hyperintense internal pallidum ventral area 0.64 0.78
30. Third ventricle enlargement 0.58 0.69
31. Punctate upper mesencephalic hyperintensities 0.48 0.73
Axial T1 32. Putamen marginal lateral rim 0.60 0.83
Values in cells are weighted kappa statistics except for (*) which is simple k.
ICC, intraclass coefficient; NNIPPS, Neuroprotection and Natural History in Parkinson’s Plus Syndromes; PD, proton density.
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from three manufacturers (GE Medical, Milwaukee, USA;
Siemens Medical Systems, Erlangen, Germany; and Philips
Medical, Best, The Netherlands) with ﬁeld strengths between 1
and 1.5 T. Images as per protocol were collected at entry for 627
patients (83% of total), including 330 patients (53%) with MSA
and 297 patients (47%) with PSP (see supplementary ﬁgure 1
available online only). Reasons for missing MRI included:
contraindication to MRI scanning; technical difﬁculties in
scanning patients due to advanced disease stage; lack of MRI
facilities (three centres) or images not performed according to
the NNIPPS acquisition protocol, as speciﬁed in table 2.
For the development of SOPs, the ﬁrst 72 of the 296 French
acquisitions were used which were subsequently found to
include 33 (46%) PSP and 39 (54%) MSA cases. These scans were
excluded from subsequent inter-rater reliability analyses
performed on the remaining 555 scans (PSP¼264, MSA¼291).
Comparison of patients with MRI to those without showed
that the sample with MRI as a whole was slightly less severely
affected with a signiﬁcant difference on Hoehn and Yahr staging
(p¼0.02). Within the sample with MRI (table 1), PSP patients
were older at inclusion and at disease onset and had shorter
duration of disease than MSA patients (p<0.002). Regarding the
Hoehn and Yahr grade and Schwab and England activity scale,
PSP patients were signiﬁcantly more severe (p<0.04 and
p<0.005, respectively) than MSA patients. Overall, 48% of the
patient population with MRI were classiﬁed in the most severe
grades (severe disability or wheelchair bound) of the Hoehn and
Yahr staging.
Histogram results
All patients’ MRIs displayed abnormalities that could be reliably
assessed on the scale. Histogram plots for each scale measure
showed that most measurements could be performed on all
images, with <7% of the 627 patient images scored as not
interpretable due to poor quality and 31 items with <2%
missing images. One item, ‘putamen marginal lateral rim’
assessment in axial T1, could not be assessed because of missing
images in 10% of cases. Signiﬁcant signs (scores 2 and 3) with
frequency >10% were present for most items, including known
signs (eg, ‘cross sign’) and previously undocumented ones (eg,
‘punctate mesencephalic hyperintensities’) (ﬁgure 1).
Reliability analysis
Among the 32 items, 25 (78%) and 31 (97%) had acceptable inter-
rater and intra-rater agreement, respectively (table 3). Intra-rater
reliability was almost perfect for four items ($0.81), substantial
for 22 (0.61#<0.81), moderate for ﬁve (0.41#<0.61) and fair for
one (¼0.38). Inter-rater reliability was substantial for nine
(0.61#<0.81), moderate for 16 (0.41#<0.61), fair for six
(0.21#<0.41) and slight for one (¼0.17).
Item redundancy
Among the seven anatomical regions that were imaged on two
separate planes and/or T1/T2 weighting, repeated scorings
showed a high correlation (r>0.7) in four, indicating that these
assessments were redundant (IVth ventricle, items 3 and 24;
cerebellar peduncles, items 7 and 21; internal globus pallidus,
items 12 and 29; mesencephalon, items 18 and 31) while three
repeated scorings (pons, items 6 and 20; aqueduct of Sylvius,
items 5 and 16; putamen, items 8 and 27) were only moderately
correlated (0.5<r<0.7) (see supplementary table 1 available
online only), indicating that each plane/weighting assessment of
these regions might visualise separate abnormalities. In order to
avoid bias from overemphasis of a particular sign (ie, to mini-
mise overloading of signs in the scale score), redundant items 7,
12, 18 and 24 were deleted from subsequent analysis.
Principal component analysis
PCA (table 4; supplementary table 2 available online only)
revealed four factors accounting for 50.5% of the total variance
and corresponding to distinct anatomical regions: F1 related to
the posterior fossa (see supplementary ﬁgure 2 available online
only); F2 related to the midbrain and third ventricle (see
supplementary ﬁgure 3 available online only); F3 related to the
lateral putamen; and F4 related to the posterior putamen,
substantia nigra and red nuclei (see supplementary ﬁgure 4
available online only). The remaining items were either not
correlated to any factors (items 29 and 31) or clustered in
a factor not found clinically or anatomically meaningful (F5:
items 19, 25 and 26; 8.2% of the total variance).
The ﬁrst four meaningful factors had acceptable internal
consistency (Cronbach a 0.75e0.93); the ﬁrst three factors
showed acceptable reliability (ICC 0.71e0.92) while the fourth
was only moderate (ICC¼0.49) (table 4).
Discriminant and predictive validity
In the overall population, extreme subgroups of disease severity
(CGI-ds borderlineemild vs severeeextremely severe) showed
signiﬁcant differences on F2 (p<0.001) and the total score
(p<0.01). A signiﬁcant interaction was found for F3; borderline
patients did not differ between MSA and PSP, while in the severe
group, MSA patients displayed higher scores than PSP patients
(ﬁgure 2). In the PSP group, MRI scale sensitivity to change in
CGI-ds showed that F2 was the most discriminant score
(ES¼0.93) followed by the total score (ES¼0.56), with the
remaining scores having small ES values (ES 0.20e0.44). In the
MSA group, F3 was the most discriminant score (ES¼0.85)
followed by the total score (ES¼0.62), with the remaining scores
having small ES values (ES 0.09e0.48).
Overall comparisons between PSP and MSA on the factorial
and total scores showed that all scores were signiﬁcantly
different, with three factors scoring signiﬁcantly higher in the
MSA group (F1, F3 and F4; p<0.0001) and one higher in the PSP
group (F2; p<0.0001) (ﬁgure 2). ES for diagnosis ranked F1 as the
most discriminant factor (ES¼1.02) followed by F2 (ES¼ 0.79),
F4 (ES¼0.49) and F3 (ES¼0.46). On the total score, MSA
patients rated signiﬁcantly higher than PSP patients
(ES¼0.78).
Among the 627 patients with usable MRI, 279 (44.5%) died
during the 3 year follow-up (PSP 46%; MSA 43%). Predictive
validity analysis using univariate Cox model analysis showed
that the total score was signiﬁcantly and linearly related to
survival in the overall population (RR (95% CI) 1.036 (1.019
to 1.053), p<0.0001) and in PSP (RR (95% CI) 1.068 (1.028 to
1.108), p<0.0007) or MSA (RR (95% CI) 1.037 (1.016 to 1.059),
p<0.0005).
Among the four-dimensional subscores, multivariate analysis
in PSP showed F2 as the only predictive subscore (RR (95% CI)
1.154 (1.072 to 1.243), p<0.0002); in MSA, both F3 (RR (95%
CI) 1.106 (1.045 to 1.171), p¼0.0005) and F2 (RR (95% CI) 1.091
(1.008 to 1.181), p¼0.031) were found to be signiﬁcantly and
independently related to survival.
DISCUSSION
The main aims of this study were to establish the feasibility of
acquiring standard imaging data in a large multicentre study of
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MSA and PSP; to show that standard imaging data can be
summarised using a semiquantitative rating scale; and to assess
the metric qualities of this scale in terms of construct validity
and reliability, as mandatory preliminary steps for using the
scale as an outcome measure in clinical trials.
In support of these goals, we have presented a standardised
MRI acquisition protocol and a set of image rating criteria to
evaluate brain lesions in MSA and PSP patients within the
context of a large prospective multicentre study. The protocol
was sufﬁciently universal to accommodate the heterogeneity of
data from the many participating centres, with acquisition time
compatible with routine clinical use, even in patients with
advanced disease. Image assessments performed on all usable
scans for reliability showed that 78% of the 32 items had
acceptable agreement for intra-rater and inter-rater reliability.
The scale was able to measure known abnormalities as well as
other previously undocumented signs. PCA revealed that 22 out
of the 32 criteria proposed could be grouped into four mean-
ingful factors, excluding four items with high redundancy and
ﬁve with unassigned signiﬁcance.
Standard image rating scale
Assessment time was deemed acceptable by all raters, and
analysis showed that signs were usable, measurable and repro-
ducible. Abnormalities were noted on every image series. As
expected, redundant signs were evident and to prevent over-
loading of signs, we deleted four highly correlated redundant
items from the ﬁnal scale. Other parameters rating the same
signs in different sequences (ie, enlargement of the aqueduct,
marginal putamen lateral and inferior rim, cerebellar atrophy,
cross sign) were less correlated. Further analyses, including
sensitivity to change, will help determine whether further scale
reduction is appropriate. Neuropathology is still in progress and
the ﬁndings will be used to conﬁrm whether these signs assess
separate abnormalities.
There were seven signs with low inter-rater reliability
(k values <0.4). These were based on signal intensity, taking
a region of white matter as reference, and thus dependent on
printing technique which is a potential source of variability.
DICOM format, now routinely available, will allow improved
standardisation and therefore reliability of such data in future
studies. In addition, the signal intensity of midbrain nuclei in T2
weighted images may not have been optimal for assessing
a small tilted midbrain structure such as the substantia nigra.32
The availability of devices at 3 T (or higher) have indicated that
basal ganglia signs such as putaminal hyperintense rims on T2
weighted images can be inﬂuenced by ﬁeld strength33 and that
high ﬁeld devices may be oversensitive in this context.34 It is
certainly possible that some additional abnormalities may be
detected by applying 3 Tor higher ﬁeld strengths but no reliable
data yet exist indicating the degree of increased sensitivity or
speciﬁcity for these purposes. Overall, improvements in reli-
ability provided by the newer technologies should improve the
performance of our scale.
Figure 1 Distribution of scores (% of
overall population) for selected a priori
redundant measurements of known
(AeB) and new signs (CeD). NA, not
assessed due to poor quality of image.
ND, not determined due to missing
images. (A, B) Ponto-cerebellar atrophy
(A) in axial (Ax) proton density (PD)
(item 6) and (B) in Ax T2 (item 20),
showing similar distribution although
better sensitivity of the Ax PD
sequence. (C, D) Punctate upper
mesencephalic hyperintensities, (C) in
Ax T2 (item 18) and (D) in coronal T2
(item 31), showing similar distribution
and sensitivity.
Table 4 Principal component analysis and reliability of factorial scores
Factors (items in factor) Anatomical dimension
Variance
(% explained)
Consistency
(Cronbach a)
Reliability
(ICC)
F1 (1e3, 6, 20e23) Brainstem and cerebellum 21.0 0.93 0.92
F2 (4e5,16e17, 30) Midbrain 10.2 0.75 0.79
F3 (8,10, 27e28, 32) Putamen 9.9 0.75 0.71
F4 (11, 13e15) Basal ganglia (other) 9.4 0.90 0.49
F5 (19, 25e26) Miscellaneous 8.2 0.48 0.76
ICC, intraclass coefficient.
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Factorial clusters
The factorial clusters extracted by component analysis are
consistent with the pathological literature.8e10 23 24 The ﬁrst
cluster (F1) consists of posterior fossa abnormalities (mainly
pontine atrophy), enlargement of the fourth ventricle, hyper-
intensity within the cerebellar peduncles and cerebellar atrophy.
These changes are consistent within image series (eg, enlarge-
ment of the fourth ventricle) and reﬂect degeneration of the
ponto-cerebellar pathways.
The second cluster (F2) centres on mesencephalic atrophy and
hypersignals associated with enlargement of the aqueduct and
periaqueductal hypersignals. These coexist with enlargement of
the third ventricle. These abnormalities are consistent with
degenerative processes involving the dentatorubrothalamic
pathway and the periaqueductal grey matter in both disorders,
as indicated in ﬁgure 2. Further insights on the pathophysio-
logical relevance of these ﬁndings will depend on analyses of the
longitudinal imaging data, with detailed clinical and patholog-
ical correlations.
Cluster F3 is composed of marginal putamen hypersignals
that are seen in both axial and coronal planes, while cluster F4
combines signs related to posterior hypointensities in the
putamen, red nucleus and substantia nigra.
Overall, three of these four factors (F1e3) showed good reli-
ability and internal consistency. F4 was highly consistent
(Cronbach 0.90) but combined four items with only fair to
moderate reliability, yielding to an overall moderate ICC, indi-
cating a need for improved procedures, including acquisition,
display media and/or readings.
It is important to note that we did not set out to test the
diagnostic sensitivity and speciﬁcity of the NNIPPS MRI scale,
so we cannot draw conclusions on the diagnostic usefulness of
this scale. Thus the next step is to test the scale prospectively
across a range of degenerative conditions, including IPD, PSP,
MSA and other multisystem disorders. Furthermore, when the
study was planned, MRI sequences such as ﬂuid attenuated
inversion recovery and diffusion weighted imaging, which might
in theory contribute to diagnostic sensitivity, were not routinely
available in the majority of centres. In addition, our protocol
was designed to minimise factors (such as duration of scanning
time) that might exclude more disabled patients and thus limit
the general relevance of our results.
In the present study, the ES of the MRI scores for comparing
severity stages were lower than those of standard clinical scales,
such as the Schwab and England Activity of Daily Living or the
Uniﬁed Parkinson’s Disease rating Scale (data not shown). These
results are not surprising given the high correlation between
these clinical scales with the CGI-ds, all of which assess func-
tion. Analysis of sensitivity to change with time should provide
a better and more relevant estimate of the MRI scale respon-
siveness. Nonetheless, our results support the fact that this MRI
scale as it stands can be used to measure severity and progression
in PSP in as much as in MSA, as shown by its good discrimi-
nation of severity stages within relevant brain structures, and
signiﬁcant prediction of survival.
Given the limited understanding of imaging changes that
correlate with disease severity or progression, some bias is likely
in our choice of items since we could not include items about
which no information was available. Both clinical and histo-
pathological analysis will help to reﬁne the signs and clusters of
signs that are most relevant for assessing disease severity in MSA
and PSP, with the possibility that further redundant or non-
discriminative signs can be removed. New pathological and
imaging studies, including analysis of the NNIPPS longitudinal
MRI data, will help to identify imaging changes of potential
importance to inform future modiﬁcations and revisions of our
scale.
With these limitations in mind, we believe that the MRI scale
assessment of disease severity has important properties for
randomised clinical trials that cannot be met by standard
functional assessments since (i) it is a more robust end point
with less liability to unblinding and (ii) quantiﬁcation of
neurodegeneration per se provides support for discriminating
between symptomatic and neuroprotective therapies, an issue
that confounds the interpretation of trials of putative disease
modifying therapies in many neurodegenerative diseases.35
In summary, we have presented a standardised imaging
protocol and image rating scale for quantifying neurodegeneration
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DISCRIMINANT VALIDITY
A B C
Figure 2 Comparison of factorial and total scores according to diagnosis at entry (A) and according to Clinician Global Impression (CGI) of disease
severity (progressive supranuclear palsy (PSP)d(B); multiple systems atrophy (MSA)d(C)). Figures within bars are number of patients in each group.
CGI disease severity score1e2¼borderlineemild impairment, score 5e6¼severeeextremely severe impairment. F1, brainstem and cerebellum; F2,
midbrain; F3, putamen; F4, other basal gangliadposterior putamen, substantia nigra, red nuclei. *p<0.05; **p<0.01; ****p<0.0001.
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in patients with Parkinson’s plus syndromes. We conclude that
the NNIPPSMRI scale can reliably and consistentlymeasureMRI
abnormalities in PSP and MSA, within the context of a large
multicentre trial.
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APPENDIX 1
NNIPPS STUDY GROUP
Coordination
European and UK: PN Leigh (London, UK). France: G Bensimon (Paris, France).
Germany: AC Ludolph (Ulm, Germany).
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Chair: PN Leigh (London, UK). Members: Y Agid, G Bensimon, M Dib, L Lacomblez,
M Vidailhet (Paris, France), D Burn (Newcastle, UK), B Landwehrmeyer, AC Ludolph
(Ulm, Germany).
Independent Data Monitoring and Safety Committee
Chair: B Asselain (Paris, France). Members: H Allain (Rennes, France), D Chadwick
(Liverpool, UK), JE Perret (Grenoble, France), C Warlow (Glasgow, UK).
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(clinicians), JL Dietemann (radiologist); Toulouse: O Rascol, M Galitzky, C Thalamas
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